Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials
| Autor: | Jing Li, Zhifeng Zhang, Wenxia Sun, Xueyan Su |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Veliparib Nausea Gastrointestinal Diseases Poly(ADP-ribose) Polymerase Inhibitors Lower risk 030226 pharmacology & pharmacy Gastroenterology Severity of Illness Index law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine Neoplasms medicine Humans Pharmacology (medical) 030212 general & internal medicine Adverse effect Randomized Controlled Trials as Topic Pharmacology Ovarian Neoplasms business.industry Cancer medicine.disease chemistry Relative risk Vomiting Female medicine.symptom business |
| Zdroj: | Journal of clinical pharmacy and therapeuticsREFERENCES. 46(2) |
| ISSN: | 1365-2710 |
| Popis: | WHAT IS KNOWN AND OBJECTIVE PARP inhibitors are currently one of the most promising PARP targeted drugs for patients with certain types of cancer. Gastrointestinal (GI) events are common adverse events for all PARP inhibitors. We conducted this meta-analysis of randomized controlled trials (RCTs) to fully investigate the incidence and the relative risk of GI events in cancer patients receiving PARP inhibitors. STUDY DESIGN Randomized controlled trials in cancer patients treated with PARP inhibitors were retrieved, and the systematic evaluation was conducted. Embase and PubMed/Medline were searched for articles published till July 2020. RESULTS Twenty-nine RCTs and 9529 patients were included. The present meta-analysis suggests that the use of PARP inhibitors significantly increases the risk of developing all-grade nausea (RR, 1.46; 95% CI, 1.29-1.66; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|